<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01282398</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-SIM-2010-06</org_study_id>
    <nct_id>NCT01282398</nct_id>
  </id_info>
  <brief_title>Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis</brief_title>
  <acronym>SIMPRO</acronym>
  <official_title>Prevention of Progression of Portal Hypertension in Compensated Cirrhosis Using Selective Hepatic Vasodilators. A Double-blind, Multicenter,Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether simvastatin is effective in the prevention
      of progression of porta hypertension in compensated cirrhosis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Decompensation of cirrhosis is associated with a dramatic reduction of survival. Progression
      of portal hypertension (PHT) is the main determinant of decompensation that appears when
      portal pressure gradient (PPG) is ≥10mmHg (clinically significant HTP). 40% of compensated
      cirrhotic patients have mild PHT. However, with progression of disease 41% develop clinically
      significant PHT. In cirrhosis, PHT results from increased resistance to blood flow, with a
      dynamic component due to decreased nitric oxide (NO) bioavailability. In advanced disease
      increased portal venous inflow also contributes to PHT. Beta-blockers have not been useful in
      compensated cirrhosis with mild PHT. In early cirrhosis, vasodilators may be more adequate.
      Statins, drugs that inhibit the activity of HMG-CoA reductase, induce selective hepatic
      vasodilation due to an enhanced bioavailability of NO. Acutely, they decreases hepatic
      resistance, while with long-term use statins decreases PPG without deleterious effects on
      systemic circulation. This multicenter, randomized, double-blind placebo-controlled study is
      aimed at assessing whether treatment with simvastatin may prevent progression of mild PHT
      (with PPG between 6 and 10 mmHg) to clinically significant PHT. Patients with compensated
      cirrhosis, without previous decompensation, without esophageal varices at risk and with PPG
      between 6 and 10 mmHg will be included. The calculated sample size is 80 patients and the
      duration of the study 4 years (2 years including and a follow-up of at least 2 year).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the treatment of portal hypertension with simvastatin may prevent progression of portal hypertension</measure>
    <time_frame>4 years</time_frame>
    <description>The main objective is to assess whether, in patients with compensated cirrhosis and mild portal hypertension (GPP between 6 and 10mmHg), the treatment of portal hypertension with simvastatin may prevent progression of portal hypertension and prevent the development of clinically significant HTP (defined GPP by a ≥ 10 mmHg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Portal hypertension complications</measure>
    <time_frame>four years</time_frame>
    <description>Development of complications related to portal hypertension (gastrointestinal bleeding related to portal hypertension, ascites, hepatic encephalopathy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>four years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Portal Hypertension.</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group will take simvastatin 40mg for at least two years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>the control group wiil take placebo pills for at least two years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>The experimental group will take 40 mg each 24 hours for at least two years.</description>
    <arm_group_label>simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>the control group wiil take placebo pills for at least two years.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver cirrhosis diagnosed by previous biopsy or by clinical, laboratory, ultrasound

          -  Portal hypertension gradient between6 mmHg and10 mmHg

          -  Absence of esophageal and gastric varices or small esophageal varices without red
             signs

          -  Absence previous episodes of gastrointestinal hemorrhage, ascites, encephalopathy or
             jaundice

          -  Written informed consent

        Exclusion Criteria:

          -  Age &lt;18 and&gt; 80 years,

          -  Presence or history of ascites, clinical or ultrasound,

          -  Previous decompensation of liver cirrhosis, ascites or SBP, bleeding varices, large
             varices, hepatic encephalopathy, jaundice,

          -  Thrombosis splenoportal,

          -  Hepatocellular carcinoma;

          -  Child-Pugh &gt;7 point

          -  Any comorbidity that leads to a restriction therapy and / or a life expectancy &lt;12
             months

          -  Absolute contraindication to treatment with statins or allergy Simvastatin;

          -  Concomitant potent CYP3A4 inhibitors (eg., itraconazole, ketoconazole, protease
             inhibitors, HIV, erythromycin, clarithromycin, telithromycin and nefazodone),

          -  Pretreatment (&lt;1 month) with simvastatin or other lipid-lowering,

          -  Previous episodes of rhabdomyolysis,

          -  Active alcoholic hepatitis,

          -  Refusal to participate in the study or the informed consent claim;

          -  Pre-treatment with beta blockers or nitrates, or endoscopic treatment for varicose
             veins or portosystemic derivations;

          -  Pregnancy and lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Candido Villanueva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Candido Villanueva, PHD</last_name>
    <phone>935565917</phone>
    <email>cvillanueva@santpau.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela Puente, MD</last_name>
    <phone>935565917</phone>
    <email>apuentesa@santpau.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Candido Villanueva, mPHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela Puente, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García-Pagán JC, Bosch J. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009 May;136(5):1651-8. doi: 10.1053/j.gastro.2009.01.043. Epub 2009 Jan 24.</citation>
    <PMID>19208350</PMID>
  </results_reference>
  <results_reference>
    <citation>Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Gao H, Makuch R; Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005 Nov 24;353(21):2254-61.</citation>
    <PMID>16306522</PMID>
  </results_reference>
  <results_reference>
    <citation>Villanueva C, Aracil C, Colomo A, Hernández-Gea V, López-Balaguer JM, Alvarez-Urturi C, Torras X, Balanzó J, Guarner C. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterology. 2009 Jul;137(1):119-28. doi: 10.1053/j.gastro.2009.03.048. Epub 2009 Apr 1.</citation>
    <PMID>19344721</PMID>
  </results_reference>
  <results_reference>
    <citation>Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernández M, Garca-Pagán JC, Rodés J, Bosch J. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology. 2004 Mar;126(3):749-55.</citation>
    <PMID>14988829</PMID>
  </results_reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2011</study_first_submitted>
  <study_first_submitted_qc>January 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2011</study_first_posted>
  <last_update_submitted>January 24, 2011</last_update_submitted>
  <last_update_submitted_qc>January 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Candido Villanueva</name_title>
    <organization>Hospital de la Santa Creu i Sant Pau</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

